Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical trial NCT04162210 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04162210
- Sponsor
- GlaxoSmithKline
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-02
- Primary completion
- 2022-09-12
- Enrollment
- 325
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.